Insulet General Counsel Unloads $49,563 in Stock (PODD)
Insulet (NASDAQ:PODD) General Counsel R Anthony Diehl sold 1,250 shares of the stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $39.65, for a total transaction of $49,562.50. Following the completion of the sale, the general counsel now directly owns 47,875 shares of the company’s stock, valued at approximately $1,898,244. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Insulet (NASDAQ:PODD) traded up 0.81% during mid-day trading on Thursday, hitting $41.06. 101,661 shares of the company’s stock traded hands. Insulet has a 52 week low of $30.18 and a 52 week high of $51.31. The stock’s 50-day moving average is $36.85 and its 200-day moving average is $40.95. The company’s market cap is $2.275 billion.
Insulet (NASDAQ:PODD) last announced its earnings data on Wednesday, May 7th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by $0.05. The company had revenue of $69.20 million for the quarter, compared to the consensus estimate of $68.47 million. During the same quarter in the previous year, the company posted ($0.20) earnings per share. The company’s revenue for the quarter was up 20.6% on a year-over-year basis. Analysts expect that Insulet will post $-0.15 EPS for the current fiscal year.
Several analysts have recently commented on the stock. Analysts at Barrington Research upgraded shares of Insulet from a “market perform” rating to an “outperform” rating in a research note on Thursday, May 15th. They now have a $40.00 price target on the stock. Separately, analysts at Jefferies Group cut their price target on shares of Insulet from $60.00 to $50.00 in a research note on Friday, May 9th. Finally, analysts at Leerink Swann cut their price target on shares of Insulet from $55.00 to $45.00 in a research note on Friday, May 9th. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $44.12.
Insulet Corporation is primarily engaged in the development, manufacturing and sale of its OmniPod Insulin Management System (NASDAQ:PODD).